Takeaways: The pCPA Letter of Intent for Anzupgo (delgocitinib cream) moves Canada closer to public reimbursement for the first topical therapy specifically indicated for moderate to severe chro...
Takeaways: Siliq’s listing under Alberta’s public drug plan expands brodalumab’s public coverage across Canada, leaving only British Columbia without provincial reimbursement and improving...
Takeaways: Roche Canada’s completion of pCPA negotiations for Perjeta (pertuzumab) in the neoadjuvant setting (with trastuzumab + chemotherapy) for HER2‑positive, locally advanced, inflammatory...
Takeaways: CDA‑AMC’s positive, conditional reimbursement recommendation for Nucala (mepolizumab) in adults with COPD and raised blood eosinophils who remain uncontrolled on ICS/LABA/LAMA triple therap...
Takeaways: Itovebi’s addition to Québec’s RAMQ list means eligible patients with advanced HR‑positive, HER2‑negative, PIK3CA‑mutated breast cancer can now access a targeted pill that, in the INAVO120 ...
Takeaways: If governments adopt the CDA-AMC recommendation, Ubrelvy could gain public coverage and expand AbbVie’s migraine footprint in Canada, creating a stronger commercial path for...
Takeaways: The decision is especially meaningful for CELYSTRA because Québec is a high-prevalence region for FCS among French Canadians, so public coverage can quickly translate into concentrate...
Takeaways: Alberta’s coverage broadens Elidel’s public-access footprint in Canada and should make it easier for dermatologists to use a non-corticosteroid topical when conventional therapies are...
Takeaways: Leqembi’s positive reimbursement step in Canada is a meaningful commercial win because it could unlock public coverage for the first disease-modifying Alzheimer’s therapy in the count...
Takeaways Sobi’s Empaveli is now positioned to move from import‑only, limited‑access status into publicly funded, pan‑Canadian treatment for C3 glomerulopathy and primary IC‑MPGN, one ...
